NEOADJUVANT ENDOCRINE THERAPY FOR PATIENTS WITH ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER

NEOADJUVANT ENDOCRINE THERAPY FOR PATIENTS WITH ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER

More than 70 % of patients with breast cancer have estrogen-receptor-positive tumors (ER+) and are considered hormone- sensitive. That is why a vast majority of patients with early operable  tumors receive adjuvant endocrine therapy. Patients with metastatic  ER+ breast cancer also receive hormone t...

Full description

Saved in:
Bibliographic Details
Main Authors: V. F. Semiglazov, V. V. Semiglazov, G. A. Dashyan, P. V. Krivorotko, V. G. Ivanov, E. K. Zhiltsova, R. M. Paltuev, L. M. Bershtein, T. Yu. Semiglazova, S. S. Yerechshenko, V. V. Klimenko, V. S. Apollonova, A. V. Komyahov, A. A. Bessonov
Format: Article
Language:Russian
Published: Russian Academy of Sciences, Tomsk National Research Medical Center 2018-07-01
Series:Сибирский онкологический журнал
Subjects:
breast cancer
neoadjuvant endocrine therapy
er+ breast cancer
hormone-dependent tumors
Online Access:https://www.siboncoj.ru/jour/article/view/758
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.siboncoj.ru/jour/article/view/758

Similar Items